C2Sense, Inc.

Name: C2Sense, Inc.
Address: Watertown, MA, 02472, US
Telephone: +16176513991

Advanced optical sensing solutions for diagnostics, authentication, and product viability assurance.

C2Sense is an advanced optical sensing company with a product portfolio that delivers solutions for rapid diagnostics, authentication, and product viability assurance to benefit the health and well-being of people worldwide. As an MIT “Tough Tech” spinout, C2Sense is committed to designing and developing products that leverage innovations in optical based sensing to help solve some of the world’s toughest challenges.

06/27/2023

Great opportunity to share our technology at event hosted by Massachusetts Institute of Technology (MIT)'s Industrial Liaison Program at Fujitsu's exclusive event highlighting future innovators. Many thanks to Fujitsu Research, MIT Industrial Liaison Program and MIT Startup Exchange for coordinating the event and the invitation for C2Sense, Inc. to present alongside Ikigai Labs, Wise Systems, and Arundo Analytics!

bit.ly/446OsQA

06/06/2023

C2Sense and Princeton BioMeditech receive NIH RADx ® Tech Funding to Advance a Digitally Connected At-Home Diagnostic Reader for Sensitivity Enhancement of an OTC COVID-19/Flu A&B Rapid Test!

The funds will be used to accelerate commercialization of a highly sensitive, fluorescent version of PBM’s Status COVID-19/Flu A&B antigen test used in conjunction with C2Sense’s Halo diagnostic reader.

WATERTOWN, Mass. and MONMOUTH JUNCTION, N.J., May 16, 2023 - C2Sense, Inc., experts in advanced optical sensing platforms and Princeton BioMeditech Corporation (PBM), a world leader in rapid, point-of-care (POC) diagnostics, announced today that they have been awarded Phase 1 funding from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Tech High Performance program. This funding will be used to advance Halo, a low-cost, high sensitivity digitally connected diagnostic reader, and convert PBM’s colorimetric OTC COVID-19/Flu A&B multiplexed lateral flow assay (LFA) to a fluorescent immunoassay (FIA).The purpose of this NIH RADx initiative, launched in April 2020, is to speed the development, commercialization and implementation of rapid and reliable technologies for COVID-19 detection. The third funding announcement from the RADx Tech program focuses on the near-term commercial deployment of easy-to-use tests that reduce reliance on serial testing and are future-proof towards new variants.

This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.

Read the full release: bit.ly/43q7ssQ

Address

Watertown, MA
02472

Telephone

+16176513991

Website

http://www.c2sense.com/

Alerts

Be the first to know and let us send you an email when C2Sense, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to C2Sense, Inc.:

Shortcuts

Want your business to be the top-listed Engineering Company in Watertown?

The C2 Story

C2Sense uses nanotechnology to develop miniaturized mobile sensing solutions for a healthier and safer world. Rapid medical diagnostics, product authentication, environmental monitoring and building/worker safety are just some of the key areas we serve. Founded in 2013 as an MIT “Tough Tech” spinout we have proven commercial solutions to help with some of the world’s toughest challenges.